Xuelin Huang1, Jie Deng2, Ting Xu2, Wenjun Xin2, Yuehong Zhang3,4, Xiangcai Ruan5,6. 1. Department of Anesthesia and Pain Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510000, Guangdong, China. 2. Guangdong Province Key Laboratory of Brain Function and Disease, Department of Physiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510000, China. 3. Department of Ophthalmology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510000, Guangdong, China. carmenzhangyh@163.com. 4. Department of Ophthalmology, The Second Affiliated Hospital of South China University of Technology, 602 Renminbei Road, Guangzhou, 510180, China. carmenzhangyh@163.com. 5. Department of Anesthesia and Pain Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510000, Guangdong, China. xc_ruan@hotmail.com. 6. Department of Anesthesia and Pain Medicine, The Second Affiliated Hospital of South China University of Technology, 602 Renminbei Road, Guangzhou, 510180, China. xc_ruan@hotmail.com.
Abstract
BACKGROUND: We previously reported a correlation between small doses of oxaliplatin penetrating onto the spinal cord and acute pain after chemotherapy. Here, we propose that MT2 within the spinal dorsal horns participates in the development of oxaliplatin-induced neuropathic pain and may be a pharmacological target for the prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN). METHODS: The rat model of CIPN was established by 5 consecutive injections of oxaliplatin (0.4 mg/100 g/day). Genetic restoration of neuron-specific metallothionein-2 was implemented 21 days before oxaliplatin treatment, and also, genetic inhibition by metallothionein-2 siRNA was performed. Mechanical allodynia and locomotor activity were assayed. Cell-specific expression of metallothionein-2, the mRNA levels of pro-inflammatory cytokines, nuclear translocation of NF-κB, the protein levels of expression of IκB-α, and interaction between IκB-α and P65 were evaluated in the spinal dorsal horns. Also, in vitro interaction of sequentially deleted IκB-α promoter with metallothionein-2 was used to assess the signal transduction mechanism. RESULTS: We found that oxaliplatin induced downregulation of metallothionein-2 in rat spinal cord neurons. By contrast, genetic restoration of metallothionein-2 in the spinal dorsal horn neuron blocked and reversed neuropathic pain in oxaliplatin-treated rats of both sexes, whereas genetic inhibition of metallothionein-2 triggered neuropathic pain in normal rats. Overall locomotor activity was not impaired after the genetic alterations of metallothionein-2. At the molecular level, metallothionein-2 modulated oxaliplatin-induced neuroinflammation, activation of NF-κB, and inactive transcriptional expression of IκB-α promoter, and these processes could be blocked by genetic restoration of metallothionein-2 in the spinal dorsal horn neurons. CONCLUSIONS: Metallothionein-2 is a potential target for the prevention and treatment of CIPN. A reduction of NF-κB activation and inflammatory responses by enhancing the transcription of IκB-α promoter is proposed in the mechanism.
BACKGROUND: We previously reported a correlation between small doses of oxaliplatin penetrating onto the spinal cord and acute pain after chemotherapy. Here, we propose that MT2 within the spinal dorsal horns participates in the development of oxaliplatin-induced neuropathic pain and may be a pharmacological target for the prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN). METHODS: The rat model of CIPN was established by 5 consecutive injections of oxaliplatin (0.4 mg/100 g/day). Genetic restoration of neuron-specific metallothionein-2 was implemented 21 days before oxaliplatin treatment, and also, genetic inhibition by metallothionein-2 siRNA was performed. Mechanical allodynia and locomotor activity were assayed. Cell-specific expression of metallothionein-2, the mRNA levels of pro-inflammatory cytokines, nuclear translocation of NF-κB, the protein levels of expression of IκB-α, and interaction between IκB-α and P65 were evaluated in the spinal dorsal horns. Also, in vitro interaction of sequentially deleted IκB-α promoter with metallothionein-2 was used to assess the signal transduction mechanism. RESULTS: We found that oxaliplatin induced downregulation of metallothionein-2 in rat spinal cord neurons. By contrast, genetic restoration of metallothionein-2 in the spinal dorsal horn neuron blocked and reversed neuropathic pain in oxaliplatin-treated rats of both sexes, whereas genetic inhibition of metallothionein-2 triggered neuropathic pain in normal rats. Overall locomotor activity was not impaired after the genetic alterations of metallothionein-2. At the molecular level, metallothionein-2 modulated oxaliplatin-induced neuroinflammation, activation of NF-κB, and inactive transcriptional expression of IκB-α promoter, and these processes could be blocked by genetic restoration of metallothionein-2 in the spinal dorsal horn neurons. CONCLUSIONS:Metallothionein-2 is a potential target for the prevention and treatment of CIPN. A reduction of NF-κB activation and inflammatory responses by enhancing the transcription of IκB-α promoter is proposed in the mechanism.
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: Cindy Tofthagen; Kristine A Donovan; Mary Ann Morgan; David Shibata; Yating Yeh Journal: Support Care Cancer Date: 2013-08-01 Impact factor: 3.603
Authors: Greg Yothers; Michael J O'Connell; Carmen J Allegra; J Philip Kuebler; Linda H Colangelo; Nicholas J Petrelli; Norman Wolmark Journal: J Clin Oncol Date: 2011-08-22 Impact factor: 44.544
Authors: Tejaswi Kandula; Michelle A Farrar; Matthew C Kiernan; Arun V Krishnan; David Goldstein; Lisa Horvath; Peter Grimison; Frances Boyle; Sally Baron-Hay; Susanna B Park Journal: Clin Neurophysiol Date: 2017-04-25 Impact factor: 3.708
Authors: Dawn L Hershman; Christina Lacchetti; Robert H Dworkin; Ellen M Lavoie Smith; Jonathan Bleeker; Guido Cavaletti; Cynthia Chauhan; Patrick Gavin; Antoinette Lavino; Maryam B Lustberg; Judith Paice; Bryan Schneider; Mary Lou Smith; Tom Smith; Shelby Terstriep; Nina Wagner-Johnston; Kate Bak; Charles L Loprinzi Journal: J Clin Oncol Date: 2014-04-14 Impact factor: 44.544
Authors: Alex Molassiotis; Hui Lin Cheng; Violeta Lopez; Joseph S K Au; Alexandre Chan; Aishwarya Bandla; K T Leung; Y C Li; K H Wong; Lorna K P Suen; Choi Wan Chan; Janelle Yorke; Carole Farrell; Raghav Sundar Journal: BMC Cancer Date: 2019-02-08 Impact factor: 4.430